Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: iPSC derived engineered T cell immunotherapies - Fate Therapeutics/Ono Pharmaceuticals

Drug Profile

Research programme: iPSC derived engineered T cell immunotherapies - Fate Therapeutics/Ono Pharmaceuticals

Alternative Names: CAR targeted, TCR-null CD8αβ+ T cells; FT 8xx; FT-ONO1; FT-ONO2; FT817; FT896; FT8solid; TCRless + TRAC-CARsolid + USE; TCRless TRAC-Targeted CAR-BCMA; TCRless TRAC-Targeted CAR19 + USE

Latest Information Update: 01 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Fate Therapeutics; Ono Pharmaceutical
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 28 Jun 2022 Fate Therapeutics expanded development and commercialisation agreement with ONO Pharmaceutical for the development of CAR NK and CAR T-celll cancer immunotherapies in
  • 11 Jan 2022 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in USA, Japan (Parenteral) (Fate Therapeutics pipeline, January 2022)
  • 05 Dec 2020 Pharmacodynamics data from preclinical studies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top